Brief: Jiangsu Recbio Technology Says It Got Clinical Trial Approval For An Omicron Vaccine In Philippines
27/06/2022 07:33
June 27 (Reuters) - Jiangsu Recbio Technology Co Ltd
2179.HK :
* CLINICAL TRIAL APPROVAL FOR MRNA COVID-19 VACCINE FOR-
OMICRON
VARIANT IN PHILIPPINES
* CLINICAL TRIAL APPROVAL FOR VACCINE FROM FOOD AND DRUG
ADMINISTRATION OF PHILIPPINES
Further company coverage: 2179.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jiangsu Recbio Technology
See all newsBrief: Jiangsu Recbio Technology To Re-Plan Timetable For HPV Vaccine Marketing Application
Brief: Jiangsu Recbio Technology Says New Drug Application For REC610 Shingles Vaccine Accepted By NMPA
Brief: Jiangsu Recbio Technology Says Liu Yong Resigned As Chair
Brief: Jiangsu Recbio Technology Says Li Bu Resigned As Executive Director
Brief: Jiangsu Recbio Technology Says Acceptance By CSRC Of Application Materials For Issuance Of Shares